1172623-99-2

Basic information

• Product Name: tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-pyran-3-yl]carbaMate
• Synonyms: tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-pyran-3-yl]carbaMate;Omarigliptin Intermediate;D-glycero-Pentitol, 1,5-anhydro-3,4-dideoxy-5-C-(2,5-difluorophenyl)-4-[[(1,1-dimethylethoxy)carbonyl]amino]-, (2ξ,5R)-;(2xi,5R)-1,5-Anhydro-3,4-dideoxy-5-C-(2,5-difluorophenyl)-4-[[(1,1-dimethylethoxy)carbonyl]amino]-D-glycero-pentitol;Omarigliptin Impurity 2
• CAS NO: 1172623-99-2
• Molecular Formula: C₁₆H₂₁F₂NO₄
• Molecular Weight: 329.3390464
• Product Categories: intermediate
• Mol File: 1172623-99-2.mol

Chemical Properties

• Boiling Point: 439.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 11.31±0.60(Predicted)
• CAS DataBase Reference: tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-pyran-3-yl]carbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-pyran-3-yl]carbaMate(1172623-99-2)
• EPA Substance Registry System: tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-pyran-3-yl]carbaMate(1172623-99-2)

Safety Data

• Hazardous Substances Data: 1172623-99-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-pyran-3-yl]carbamate is used as a potential pharmaceutical compound for its potential bioactive properties. The presence of a carbamate group and fluorinated phenyl group may contribute to its interaction with biological targets, making it a candidate for drug development.
Used in Chemical Research:
tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-pyran-3-yl]carbaMate is used as a research tool in the field of organic chemistry, particularly for studying the effects of chirality and fluorination on molecular properties and reactivity. Its unique structure allows chemists to explore new synthetic pathways and investigate its potential applications in various chemical processes.
Used in Material Science:
Tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-pyran-3-yl]carbamate may be used in the development of new materials with specific properties, such as improved stability or reactivity, due to its fluorinated aromatic characteristics and chiral nature. This could be particularly relevant in the fields of polymer science and advanced materials.

Upstream product

• 1172623-98-1 tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-3,4-dihydro-2H-pyran-3-yl]carbamate 
• 1172623-95-8 (±)-tert-butyl (1-(methoxy(methyl)amino)-1-oxopent-4-yn-2-yl)carbamate 
• 50428-03-0 D,L-propargylglycine 
• 61172-66-5 2-((tert-butoxycarbonyl)amino)pent-4-ynoic acid 
• 951127-25-6 N-[(2R,3S)-2-(2,5-difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2646-90-4 2,5-difluorobenzaldehyde 
• 61172-66-5 (S)-2-(tert-butoxycarbonylamino)pent-4-ynoic acid 
• 208520-80-3 (S)-tert-butyl (1-(methoxy(methyl)amino)-1-oxopent-4-yn-2-yl)carbamate 
• 171922-16-0 ethyl 2-[(diphenylmethylidene)amino]pent-4-ynoate 
• 167904-79-2 methyl (R,S)-2-(N-diphenylmethylidene)aminopent-4-ynoate 
• 100860-41-1 ethyl 2-aminopent-4-ynoate 
• 1172623-96-9 (±)-tert-butyl (1-(2,5-difluorophenyl)-1-oxopent-4-yn-2-yl)carbamate 

Downstream Products

• 951127-25-6 N-[(2R,3S)-2-(2,5-difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester 
• 1107484-78-5 tert-butyl ((2R,3S,5S)-2-(2,5-difluorophenyl)-5-(pyrrolo[3,4-c]-pyrazol-5(1H,4H,6H)-yl)tetrahydro-2H-pyran-3-yl)carbamate 
• 1226781-44-7 Omarigliptin 
• 1226781-87-8 tert-butyl {(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-yl}carbamate 

Relevant articles and documents

Ternary fused ring substituted six-membered ring derivatives and their use in medicine

The invention relates to a fused tricyclic substituted amino six-membered ring derivative and application thereof in medicine, particularly a fused tricyclic substituted amino six-membered ring derivative shown in a formula (I) or stereoisomers and pharmaceutically acceptable salts or pro-drugs of the derivative, a pharmaceutical composition comprising the derivative and use of the derivative in preparing a dipeptidyl peptidase IV (DPP-IV) inhibitor in medicine, wherein the substituents in the formula (I) are defined as in the description. The formula (I) is shown in the description.

Synthesis method of chiral amino pyrone compounds

The invention relates to a synthesis method of chiral amino pyrone compounds, and a pure chiral structure of an intermediate of the reaction namely N-Boc-1-(2,5-difluorophenyl)-1-oxo-2-S-aminopentyl-4-yne. The synthesis reaction formula is represented in the description.

AMINO PYRANOID RING DERIVATIVE AND COMPOSITION AND USE THEREOF

The present invention relates to an amino pyran ring derivative and a composition and use thereof, and in particular, to an amino pyran ring derivative represented by general formula (I) or a stereoisomer, a pharmaceutically acceptable salt or a prodrug thereof, a pharmaceutical composition comprising the derivative, and their medical use in the manufacture of a di-peptidyl peptidase IV (DPP-IV) inhibitor, in formula (I) the substituents are defined the same as those in the specification.

PROCESS FOR THE PREPARATION OF OMARIGLIPTIN

The present invention provides a process for preparing omarigliptin.

Amino 6-membered ring derivative and pharmaceutical applications thereof including the use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor

The present invention relates to an amino 6-membered ring derivative and pharmaceutical applications thereof, which specifically relates to the amino 6-membered ring derivative represented by the general formula (I) or stereoisomers thereof, pharmaceutically acceptable salts thereof, a prodrug, a pharmaceutical composition comprising the derivative, and the pharmaceutical use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor, wherein the definition of each substituent in the general formula (I) is the same as described in the specification.

Three-membered fused ring substituted amino six-membered ring derivative and medicine applications thereof relates to a three-membered fused ring substituted amino six-membered ring derivative as shown in the general formula

The present invention relates to a three-membered fused ring substituted amino six-membered ring derivative and medicine applications thereof, and more particularly to a three-membered fused ring substituted amino six-membered ring derivative as shown in the general formula (I) or a stereoisomer of the derivative, a pharmaceutically acceptable salt, a prodrug, a medicinal composition containing the derivative and an application of the derivative to preparation of the medicine, namely a dipeptidyl peptidase IV(DPP-IV) inhibitor, wherein the definitions of the various substituents in the general formula (I) are the same as those in the specification.

Pyrrole imidazole ring derivative and medical use thereof wherein the compound represented by the general formula (I) has excellent inhibitory effect on and selectivity of dipeptidyl peptidase IV(DPP-IV)

The present invention relates to a pyrrole imidazole ring derivative and medical use thereof, more particularly a pyrrole imidazole ring derivative represented by the general formula (I) or stereoisomers thereof, pharmaceutically acceptable salts thereof, prodrugs, pharmaceutical compositions containing the derivative, and pharmaceutical applications for the preparation of dipeptidyl peptidase IV(DPP-IV) inhibitors, wherein the definitions of all substitution groups in general formula (I) are the same as those defined in the specification.

Aminopyran ring derivative and its composition and application wherein the dipeptidyl peptidase IV (DPP-IV) inhibitor is used for preparing the drugs for treating metabolic diseases

The present invention relates to an aminopyran ring derivative and its composition and application, specifically speaking, relating to the aminopyran ring derivative represented by the general formula (I) or its stereoisomer, pharmaceutically acceptable salt, prodrug, pharmaceutical composition containing the derivative and the preparation of dipeptidyl peptidase IV (DPP-IV) inhibitor for medical use, wherein the definitions of the substituents in the general formula (I) are the same as those defined in the patent specification.

Amino six member ring derivatives and their use in medicine (by machine translation)

The invention relates to a six-member ring amino derivatives and its application in medicine, specifically relates to the general formula (I) as shown by the six-member ring of the amino derivative or its stereoisomer, pharmaceutically acceptable salt, prodrug, pharmaceutical composition containing the derivative of the dipeptidyl peptidase IV and the preparation (dPP CGI-iV) inhibitors of their medical use, wherein the general formula (I) definition of each substituent in the definition of the description of the same. (by machine translation)

Pyran derivative salt or its salt hydrate and its preparation and use (by machine translation)

The invention relates to a benzopyran derivative salt or its salt hydrate and its preparation and application, and in particular relates to dipeptide kinase - IV inhibitor a pharmaceutically acceptable salt or its salt hydrate, and its preparation method and application, further for the purposes of formula (I) as shown in the salt or its salt hydrate and its preparation method and application. (by machine translation)